Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT04639388
Recruiting Not applicable

Understanding of Psychotic Disorders in Children With 22q11.2DS

NCT04639388 · tracked via the Priya Life Science France tracker
Sponsor
Hôpital le Vinatier
Phase
Not applicable
Started
2020-11-13
Last updated
2025-07-30

Condition(s) studied

22q11.2 Deletion Syndrome

Investigational drug(s) / intervention(s)

neuropsychological testing, questionnaires and experimental tasks

neuropsychological testing, questionnaires and experimental tasks: Neuropsychological testing (the Sky Search subtest from the Test of Everyday Attention for Children (TEA-Ch); the Overlapping lines task of Rey; auditory attention of NEPSY II battery); questionnaires completed by the children's legal representatives to assess behavior; experimental tasks evaluating gaze direction and facial expression recognition

Study summary

The study PremiCeS22 will investigate the prodromal signals at the onset of psychotic disorders of children with 22q11.2 deletion syndrome

Eligibility

Sex
ALL
Min age
4 Years
Max age
13 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Diagnosis of 22q11.2 deletion syndrome or no developmental disease * Aged from 4 to 13 years old * French language Exclusion Criteria: * Diagnosis of intellectual deficiency according to DSM 5 criteria * Drug prescribed for somatic condition that could influence cerebral functioning

Primary outcome measure(s)

  • The Screen for child Anxiety Related Emotional Disorders (SCARED) — Day 1
    Scale assessing behavioral prodromes or warning signs of hallucinations in psychotic disorders A psychometric study is then carried out on this questionnaire in order to validate it with parents of children carrying 22q11.2DS.
  • facial expression recognition task — Day 1
    Proportion of correct responses in experimental tasks evaluating gaze direction and facial expression recognition

Trial sites (1)

FacilityCityRegionStatus
Hopital Vinatier Lyon Auvergne-Rhône-Alpes Recruiting

More Hôpital le Vinatier trials in France

Trajectories and Reactions of Users and Relatives Consulting French Youth Addiction Services Recruiting
Psychoeducation Program for Family Caregivers Coordinated by an APRN Recruiting
Metabolomics During ElectroConvulsivoTherapy Recruiting
Impact of EDEN College Courses on the Quality of Life of Voice-Hearers Recruiting
Feasibility Study of a Combined Intervention for Suicidal Inpatients in Psychiatric Crisis Units. Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04639388 on ClinicalTrials.gov ↗ ← All trials in France